Envista Holdings Corp
HealthcareNYSE:NVST · New York Stock Exchange
+$0.10 today
Vol 2.17M · Avg 2.97M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.8B of revenue converted into $67.7M of net income for the selected period. Gross margin is 55.1% and net margin is 2.3%, showing how much revenue survives after costs and taxes. EPS is $0.41, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B +8.3% | $2.5B -2.2% | $2.6B -0.1% | $2.6B +2.4% | $2.5B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.2B +9.3% | $1.1B +0.3% | $1.1B +3.3% | $1.1B +3.3% | $1.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.5B +7.5% | $1.4B -4.1% | $1.5B -2.5% | $1.5B +1.8% | $1.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 55.0% -0.4pp | 55.4% -1.1pp | 56.5% -1.4pp | 57.9% -0.4pp | 58.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $114.0M +15.0% | $99.1M +5.7% | $93.8M -6.3% | $100.1M -0.4% | $100.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.2B +1.8% | $1.1B +10.4% | $1.0B +0.1% | $1.0B +3.9% | $989.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.3B -47.7% | $2.4B +71.2% | $1.4B +21.4% | $1.2B +1.1% | $1.2B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $116.0M -5.8% | $123.1M -9.2% | $135.6M -1.6% | $137.8M +11.5% | $123.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $329.8M +18.0% | $279.5M -39.6% | $463.0M -7.0% | $497.7M +0.3% | $496.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 12.1% +1.0pp | 11.1% -6.9pp | 18.0% -1.3pp | 19.4% -0.4pp | 19.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $225.7M +121.7% | -$1.0B -3395.9% | $31.5M -90.1% | $319.2M +4.2% | $306.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 8.3% +49.7pp | -41.4% -42.6pp | 1.2% -11.2pp | 12.4% +0.2pp | 12.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $36.6M -21.1% | $46.4M -26.8% | $63.4M +65.1% | $38.4M -29.0% | $54.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$48.5M -4.3% | -$46.5M +46.2% | -$86.4M -144.8% | -$35.3M +31.7% | -$51.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $177.2M +116.3% | -$1.1B -1875.8% | -$54.9M -119.3% | $283.9M +11.6% | $254.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 6.5% +49.7pp | -43.2% -41.1pp | -2.1% -13.2pp | 11.1% +0.9pp | 10.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $130.2M +284.1% | $33.9M -25.2% | $45.3M -1.3% | $45.9M +610.0% | -$9.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $47.0M +104.2% | -$1.1B -1016.4% | -$100.2M -141.2% | $243.1M -28.6% | $340.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 1.7% +46.3pp | -44.6% -40.7pp | -3.9% -13.4pp | 9.5% -4.1pp | 13.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +104.3% | -$7 -983.3% | -$1 -141.1% | $1 -10.4% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +104.3% | -$7 -983.3% | -$1 -144.8% | $1 -9.5% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $168.0M -2.4% | $172.2M +3.2% | $166.9M +2.5% | $162.9M +1.1% | $161.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $169.2M -1.7% | $172.2M +3.2% | $166.9M -6.0% | $177.6M +0.0% | $177.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
Alignment Healthcare, Inc.
NASDAQ:ALHC
$4.08B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
ICU Medical, Inc.
NASDAQ:ICUI
$3.55B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
GRAIL, Inc.
NASDAQ:GRAL
$2.57B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NVST generate?
Envista Holdings Corp (NVST) reported $2.72B of revenue in fiscal 2025.
Is NVST profitable?
Envista Holdings Corp (NVST) reported $47.00M of net income, with a net margin of 1.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.